The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

In recent years, the high heterogeneity of colorectal cancer (CRC) has become evident.
Hence, biomarkers need to be developed that enable the stratification of patients with CRC …

Colorectal cancer (CRC) is a disease in which pathogenesis is influenced by genetic and
epigenetic events that occur with tumor initiation and progression. Large variation exists in …

Colorectal cancer (CRC) is a leading cause of death among cancer patients. This
heterogeneous disease is characterized by alterations in multiple molecular pathways …

Colorectal cancer (CRC) is the third most common cancer diagnosed worldwide and is
heterogeneous both morphologically and molecularly. In an era of personalized medicine …

The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …

Personalized cancer medicine is becoming increasingly important in colorectal cancer
treatment. Especially for targeted therapies, large variations between individual treatment …

Colorectal cancer (CRC) is a leading cause of death worldwide, despite progress made in
detection and management through surgery, chemotherapy, radiotherapy, and …

Rapidly growing insights into the molecular biology of colorectal cancer (CRC) and recent
developments in gene sequencing and molecular diagnostics have led to high expectations …

Colorectal cancer is the third most common cancer worldwide, with 1.36 million people
diagnosed in 2012. The prognosis of colorectal cancer is better with an earlier diagnosis …